Entrectinib Nets 69% ORR in Children with ROS1-Fusion Solid & CNS Tumors
- Trial ID
- NCT02650401 on ClinicalTrials.gov
- Cancer type
- Solid Tumors
- Related trial IDs
- NCT04589845NCT02568267
- Published in
- New in Oncology - June 6, 2025
Entrectinib, an oral TRK/ROS1 inhibitor, was pooled across the phase 1–2 STARTRK-NG (NCT02650401), TAPISTRY (NCT04589845), and STARTRK-2 (NCT02568267) trials. Across 26 ROS1-fusion patients (<18 y) there was a 69% objective response rate (15% CR; 54% PR) with median response time of 1.8 mo, and median OS not reached. Grade 3/4 treatment-related events were mainly weight gain, anemia, and fractures (23%).
Take home
These rapid, durable responses underscore the value of routine ROS1 testing in pediatric solid and CNS tumors, mostly glioma at 0.3% to 1% of cancers—and spotlight bone-health monitoring as entrectinib usage expands.
Source: Read the original publication
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings